NEW NATIONWIDE STUDY WILL EVALUATE EFFECT OF ANTIOXIDANTS AND FISH OIL ON PROGRESSION OF AGE-RELATED MACULAR DEGENERATION (AMD)

[Date Prev][Date Next][Thread Prev][Thread Next][Date Index][Thread Index]

 



U.S. Department of Health and Human Services 
NATIONAL INSTITUTES OF HEALTH 
NIH News 
National Eye Institute (NEI) 
<http://www.nei.nih.gov/>

FOR IMMEDIATE RELEASE: Thursday, October 12, 2006

CONTACT: National Eye Institute, 301-496-5248, <neinews@xxxxxxxxxxx>

NEW NATIONWIDE STUDY WILL EVALUATE EFFECT OF ANTIOXIDANTS AND FISH OIL
ON PROGRESSION OF AGE-RELATED MACULAR DEGENERATION (AMD)
Nearly 100 Clinical Centers Are Now Seeking 4,000 Study Participants
Ages 50 - 85 Who Have AMD 

The National Institutes of Health (NIH) announces a nationwide study to
see if a modified combination of vitamins, minerals, and fish oil can
further slow the progression of vision loss from AMD, the leading cause
of vision loss in the United States for people over age 60. This new
study, called the Age-Related Eye Disease Study 2 (AREDS2), will build
upon results from the earlier Age-Related Eye Disease Study (AREDS). The
original study results were released five years ago today.  The study
found that high-dose antioxidant vitamins and minerals (vitamins C and
E, beta-carotene, zinc, and copper), taken by mouth, reduced the risk of
progression to advanced AMD by 25 percent, and the risk of moderate
vision loss by 19 percent. 

AREDS2 will refine the findings of the original study by adding lutein
and zeaxanthin (plant-derived yellow pigments that accumulate in the
macula, the small area responsible for central vision near the center of
the retina) and the omega-3 fatty acids DHA and EPA (derived from fish
and vegetable oils) to the study formulation. The main study objective
is to determine if these nutrients will decrease a person's risk of
progression to advanced AMD, which often leads to vision loss. Previous
observational studies have suggested these nutrients may protect vision.

"Vision loss from AMD is an important public health issue. This study
may help us find a better way to treat this devastating disease," said
Elias A. Zerhouni, M.D., director of the NIH.

AMD damages the macula. As the disease progresses, it blurs the
patient's central vision. AMD can take two forms, wet and dry. Wet AMD
is caused by the abnormal growth of blood vessels under the macula. This
leads to rapid loss of central vision. Wet AMD is considered to be
advanced AMD and is more severe than the dry form. Dry AMD, the more
common form, occurs when the light-sensitive cells in the macula slowly
break down. Untreated dry AMD can progress into wet AMD. 

Paul A. Sieving, M.D., Ph.D., director of the National Eye Institute
(NEI) at NIH, said, "Nearly two million Americans have vision loss from
advanced AMD, and another seven million with AMD are at substantial risk
for vision loss. In the AREDS study, we found a combination of vitamins
and minerals that effectively slowed the progression of AMD for some
people. Now, we will conduct this more precisely-targeted study to see
if the new combination of nutrients can reduce AMD progression even
further. This study may help people at high risk for advanced AMD
maintain useful vision for a longer time."

Emily Y. Chew, M.D., study chair and deputy director of the Division of
Epidemiology and Clinical Research at the NEI said, "The AREDS2 study is
seeking 4,000 people between 50 and 85 years of age with AMD in both
eyes, or advanced AMD in one eye. They must be available for yearly eye
examinations for at least five years. Until we get the results from
AREDS2, we encourage people with AMD to visit their eye care
professional to see if they need to take the AREDS vitamin and mineral
formulation. This alone could save more than 300,000 people from vision
loss over the next five years." 

For a list of study centers, eligibility requirements, and other
information, go to: <http://www.nei.nih.gov/AREDS2>, or call
1-877-AREDS-80 (1-877-273-3780).

The National Eye Institute (NEI) is part of the National Institutes of
Health (NIH) and is the Federal government's lead agency for vision
research that leads to sight-saving treatments and plays a key role in
reducing visual impairment and blindness. For more information, visit
the NEI Website at <http://www.nei.nih.gov/>.
 
The National Institutes of Health (NIH) -- The Nation's Medical Research
Agency -- includes 27 Institutes and Centers and is a component of the
U.S. Department of Health and Human Services. It is the primary federal
agency for conducting and supporting basic, clinical and translational
medical research, and it investigates the causes, treatments, and cures
for both common and rare diseases. For more information about NIH and
its programs, visit <www.nih.gov>.

##

This NIH News Release is available online at:
http://www.nih.gov/news/pr/oct2006/nei-12.htm.

To subscribe (or unsubscribe) from this list, go to
http://list.nih.gov/cgi-bin/wa?SUBED1=nihpress&A=1.

[Index of Archives]     [CDC News]     [FDA News]     [USDA News]     [Yosemite News]     [Steve's Art]     [PhotoForum]     [SB Lupus]     [STB]

  Powered by Linux